Related Tags >> anthrax vaccine FDA Emergent BioSolutions Siga Technologies

Pharmathene News

Most Popular Pharmathene Story

Regulators focusing on transgenic animals

July 30, 2007 — 5:59am ET

Genetically engineered animals are producing a range of therapies for human use, and The New York Times catches up on the action at companies like Read more...

Pharmathene Press Releases

PharmAthene, Inc.'s rPA Anthrax Vaccine Program Demonstrates 36 Month Product Stability
PharmAthene, Inc. Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
BIO-Europe Spring 2011 Spotlight Panels Focus on Innovative Paths to Market
PharmAthene, Inc. Announces Pricing of $15 Million Public Offering
U.S. Government Accountability Office Denies Competitor Protest of SparVax(TM) Contract Modification

Latest Headlines

PharmAthene wins ruling in fight over $78M anthrax contract
June 9, 2010
Feds' anthrax shift triggers sharp drop in developers' shares
December 9, 2009
PharmAthene snares two vaccines in buyout
March 25, 2008
C&L: Memory CEO steps down
February 13, 2008
PharmAthene finds backers for research pact
January 14, 2008
ALSO NOTED: Genzyme has made best offer for Bioenvision; Pfizer wants investigators to pursue ex-employee; GSK licenses IP; and
September 27, 2007
Regulators focusing on transgenic animals
July 30, 2007

Paid Research Reports

More Research Reports >>